Journal
DRUG DISCOVERY TODAY
Volume 23, Issue 9, Pages 1666-1671Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.05.024
Keywords
-
Categories
Funding
- CAPES
- CNPq
- FAPDF
- FUNDECT
- UCB
- UCDB
- National Council of Technological and Scientific Development (CNPq)
- Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) - Brazil [300583/2016-8]
Ask authors/readers for more resources
Since the early 19th century, host-defense peptides (HDPs) have been known to play a crucial role in innate host defense. Subsequent work has demonstrated their role in adaptive immunity as well as their involvement in cancer and also a number of inflammatory and/or autoimmune diseases. In addition to these multiple functional activities, several studies have shown that HDP accumulation might be correlated with various human diseases and, therefore, could be used as a biomarkers for such. Thus, research has aimed to validate the clinical use of HDPs for diagnosis, prognosis, and further treatment. In this review, we outline the most recent findings related to the use of HDPs as biomarkers, their clinical and epidemiological value, and the techniques used to determine the levels of HDPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available